History
Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, percentages, share counts, and dates are unitless and unchanged.
History
Mirae Corporation pioneered Korean semiconductor test handlers in 1983 and quietly compounded as a small specialist for forty years — then in mid-2023 collapsed (revenue down 61%, a $24.3M net loss), was sold to a new controlling group (ROA-linked Nextern Roll Korea), recapitalised through dilution and a 16:1 reverse split, and re-emerged in FY2025 as a $35.0M-revenue China supplier with 56.5% of sales going to a single Chinese DRAM customer. The story management tells is "back to focus on our core ATE business after side ventures didn't pan out." The story the filings actually show is a near-death cycle, an ownership transfer, an aggressive capital structure rebuild, and a customer concentration so extreme it is now the dominant fact about the business. Credibility has improved versus the pre-2023 governance regime — the new team is unusually candid in print about side-venture failures — but the present-day equity story is a single-customer China bet wearing a 42-year-old Korean test-handler brand.
1 — The Narrative Arc
The current chapter of this business began in July 2023, when Nexturn Biosciences took control from prior owner Kwang Lim and Lee Chang-jae was installed as Representative Director on the same day. Everything in the post-2023 ownership chain, capital structure, customer base, and reported strategy resets from that moment. The legacy 1983–2022 chapter is a separate company in most respects that matter for valuation.
Inflection point — July 2023. Three things happened in the same week: (1) controlling shareholder changed from Kwang Lim Co. to Nexturn Biosciences on 12 July 2023, (2) the entire executive slate was replaced at the 13 July extraordinary shareholder meeting and Lee Chang-jae became CEO, (3) the articles of incorporation were rewritten to add EV-parts, AI-healthcare, mining, ESS, and renewable energy as new business purposes. This date anchors every subsequent judgement about this management team's track record — the FY2023 collapse belongs to the prior regime; the FY2024–FY2025 recovery belongs to current leadership.
2 — What Management Emphasised — and Then Stopped Emphasising
Mirae does not host earnings calls or issue forward guidance the way US issuers do. The cleanest evidence of what management is willing to bet on lives in the articles of incorporation — specifically, in the list of officially declared business purposes that the board added and shareholders ratified. Each addition was sold as future-growth optionality; the subsequent deletion (or the explicit footnote that "we judged this has no synergy with our core business") is the recantation.
The pattern is unusually clear: every two years Mirae's board adds a basket of trendy adjacent businesses — masks during COVID, DeFi during the 2022 crypto top, AI-healthcare and EV-battery materials during the 2023 EV/AI cycle — and then quietly deletes the ones that "do not have synergy" once the cycle rolls over. None of these additions has ever produced disclosed revenue. The fact that the issuer itself prints the recantation in the next year's articles section is the most credibility-supportive aspect of the whole disclosure regime — it would be easy to leave the dead purposes on the books indefinitely. Each cycle, however, is an opportunity-cost statement: while management was adding mask manufacturing and DeFi, competitor Hanmi Semiconductor was building the high-bandwidth-memory test handler business that drove its multi-billion-dollar re-rating.
3 — Risk Evolution
The risk language in the annual reports themselves is shorter than US-style 10-K risk-factors sections and changes less. What changes is which risks are now empirically dominant in the underlying financials and contracts, regardless of how they are described. The heatmap below scores each risk on a 0–3 scale based on disclosure intensity and the financial weight of the underlying exposure.
The single most important shift: the company has traded operational risk (memory cycle, customer capex) for political and counterparty risk (China concentration, export control, single-customer receivables). Both classes of risk are real, but they are managed differently and price differently. A reader who was comfortable with Mirae in 2021 because "Korean ATE specialist with SK Hynix exposure" should not be comfortable in 2025 for the same reason — it is now closer to "Chinese DRAM-equipment subcontractor with a Korean listing".
4 — How They Handled Bad News
Mirae's disclosure regime is light on press releases and earnings commentary, so "handling bad news" mostly means how items are presented in the formal Business Report. There are three episodes worth comparing.
"신사업의 수익성, 기술성, 경제성 등 주 사업과의 시너지효과가 없다고 판단되어 [추진계획은 없습니다 / 삭제하였습니다]."
"We judged the new business has no profitability, technology or economic synergy with our core business, so [we have no plans to pursue it / we have removed it]." — recurring footnote across the 2021, 2022, and 2023 article-of-incorporation additions.
That sentence is the most informative thing the company says about itself. It tells you the additions were either pure governance theatre or genuinely tried and failed; it tells you the next basket of additions (whatever it is) should be discounted in the same way; and it tells you the board is willing to admit it in print. None of those facts is good news on its own, but the candour is genuine.
5 — Guidance Track Record
Mirae does not issue numeric forward guidance. What it does issue are (a) business-purpose additions that imply intended entry into a market, (b) capital-raise commitments (CBs, rights offerings), and (c) contract-disclosure announcements that show order book conversion. Treating each of those as an implicit promise allows a track record to be built.
Credibility score (1-10)
Implicit promises tracked
Delivered
Missed (side-venture entries)
Credibility: 5 / 10. Current management (Lee Chang-jae and the Nextern-Roll Korea-installed board, in place since July 2023) has a perfect record on the things they actually do — capital raises that close, contracts that ship, an operational turnaround that arrived on schedule. They are also unusually willing to admit, in print, that their side-venture additions did not work. Against that, every diversification ambition the board has ever asked shareholders to approve has been quietly walked back; the headline financial recovery rests on one Chinese customer; and the dilution-then-reverse-split path destroyed per-share economics that the reverse split does not actually rebuild. A 5 reflects high process honesty paired with a strategy whose durability rests on something — Chinese DRAM capex — that management cannot itself control or even publicly defend.
6 — What the Story Is Now
The current Mirae story is simpler than at any point since 2021, and more concentrated than at any point in its 42-year history. It is a Korean-listed Chinese-DRAM-equipment supplier with a single dominant customer, a recovered but fragile operating profile, and a clean — if recently rebuilt — capital structure.
FY2025 revenue ($M)
FY2025 net income ($M)
Top-customer revenue share (YILINING)
ATE share of revenue
Shares outstanding (M, post-split)
Largest shareholder (Nextern Roll)
What has been de-risked (believe this): the operational franchise is real, the 2023 loss was a cycle-and-ownership event not a fundamental business failure, the ATE backlog converts at high gross margin, the new owners have invested rather than asset-stripped, and the disclosure regime is more candid than peers.
What is now the central risk (discount the implied steady-state): 56.5% of revenue from one Chinese customer (YILINING / CXMT) is not a steady-state mix; FY2025 operating cash flow was negative $3.6M and free cash flow negative $15.2M despite a record P&L — i.e. the income statement and the cash statement disagree, and the difference is China receivables and Korean capex; the next basket of "diversification" business-purpose additions, whenever it comes, should be assumed never to be pursued.
The cleanest summary: management has done well at what they directly control, and the business is now exposed to things they do not control. That is a different equity story than the one Mirae told for the first 40 years of its existence, and the reader who is underwriting the FY2025 P&L as a run-rate should be sure they are underwriting the China-DRAM-capex cycle, not the Korean-test-handler franchise. They are no longer the same thing.